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Efficacy of intrarenal ACE-inhibition estimated from the renal re-
sponse to angiotensin I and II in humans. Recent studies on the nature of
the renin-angiotensin system (RAS) in animals have led to the concept
that systemic and intrarenal RAS can be influenced to different degrees by
angiotensin converting enzyme (ACE) inhibitors. Assessment of efficacy
of intrarenal ACE inhibition by ACE inhibitors in humans is necessarily
indirect and has not been reported. We therefore monitored the renal
response to acute angiotensin (Ang) I infusion in volunteers taking 20 mg
enalapril twice daily, and related the responses to the obtained incre-
ments in plasma Ang II levels. Ang I infusion rates of 4, 8, 16, and 32
pmollkglmin caused gradual increments in plasma Ang I (maximal change
from 26 18 to 578 120 pmollliter, P < 0.05) and, despite treatment
with enalapril, also of Ang II (from 3 ito 29 5 pmollliter, P < 0.05).
This was associated with large reductions in renal plasma flow (para-
aminohippurate clearance), filtration fraction, maximal urine flow, sodium
excretion, lithium and uric acid clearance, and increments in mean arterial
pressure and plasma aldosterone (P < 0.05 for each variable). Strong
correlations existed between the changes in either variable and the
increment in plasma Ang II. Infusions of Ang II at 1 and 4 pmollkglmin in
the same subjects caused comparable increments in plasma Ang II and
had similar physiological effects as found during the Ang I infusion.
Analysis of covariance of the changes in plasma Ang II and each of the
measured variables revealed no differences between Ang I and Ang II
infusions. Since Ang I had no functional effects in the kidney independent
of the increments in plasma Ang II, additional intrarenal Ang I to Ang II
conversion in the present experimental setting is unlikely. This protocol
provides an indirect method to assess efficacy of intrarenal ACE inhibition
in humans.
Administration of angiotensin converting enzyme (ACE) inhib-
itors is aimed at suppression of plasma and tissue angiotensin
(Ang) II formation. A variety of experimental conditions have
recently been reported, where activity of the renin-angiotensin
system (RAS) in plasma, vessel wall and kidney was differentially
affected by ACE inhibitor administration [1—51. Consequently,
plasma ACE activity is insufficient to assess the efficacy of ACE
inhibitors. At least two different mechanisms can explain the
dissociation of plasma and tissue RAS activity. One is formed by
different ACE activities in plasma and tissues due to disparate
degrees of inhibition of the enzyme or to differential upregulation
of ACE expression, which follows administration of ACE inhibi-
tors [6—8]. Alternatively, Mg II generation not dependent on
ACE [9, 10] could be differentially up-regulated in plasma and
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tissues. As a consequence, the marked elevation of Ang I levels
which accompany ACE-inhibition may affect plasma, vascular and
renal Mg II formation differently.
Evidence is accumulating supporting the concept that the renal
actions of the RAS form a potent hypertensinogenic mechanism
by enhancing proximal tubular sodium reaborption and increasing
tubuloglomerular feedback responsiveness [11—131. Suppression
of these synergistic renal effects of angiotensin by administration
of ACE inhibitors is probably essential to enable the kidney to
excrete sodium at lower blood pressure. Several studies have
indicated persistent intrarenal Mg II formation despite adequate
systemic ACE inhibition [14—16]. This suggests that under partic-
ular conditions of systemic inhibition of Ang II formation, the
renal RAS can still contribute to sodium retention and to the
maintenance of hypertension.
Therefore, the present study was designed to investigate
whether intrarenal Mg II formation can exceed plasma Ang II
formation in healthy humans during the administration of a high
dose of the ACE inhibitor enalapril and infusion of Mg I.
Because of the impossibility to assess the human intrarenal RAS
directly, functional responses of mean arterial pressure, and renal
hemodynamic and excretory functions were evaluated during
infusion of Mg I and II. First, we tried to define the relationship
between plasma Mg II levels and these functional responses by
infusion of Ang II. Then, Mg I was infused during administration
of enalapril, and plasma Mg II levels and functional responses
were evaluated. It was anticipated that, if inhibition of intrarenal
Ang II formation would be less than that of systemic Mg II
formation, infusion of Mg I would have more pronounced actions
on renal hemodynamics and sodium handling than could be
expected from the plasma Mg II levels. In particular, intrarenal
Mg II formation exceeding systemic Mg II formation during
Mg I infusion would result in steeper relationships between
plasma Ang II and renal hemodynamics or sodium and water.
Methods
Subjects
Seven healthy volunteers, one female and six males, age range
20 to 25 years, were selected after hypertension and other diseases
were excluded by appropriate clinical and laboratory investiga-
tions. The protocol was approved by the Hospital Ethical Com-
mittee for Studies in Humans, and informed consent was obtained
from each participant.
The subjects received a diet containing a high sodium content
(340 mmol per day) to minimize endogenous plasma Mg I
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formation and the hemodynamic effects of enalapril. The diet was
provided by the metabolic ward where the subjects returned daily
to deliver 24-hour urine collections. In addition, they received
enalapril 20 mg b.i.d. On days 5 and 6 of this regimen clearance
studies were carried out, during which either Ang I or Mg II was
infused (see below). These studies were performed in the morn-
ing, after ingestion of 400 mg lithium carbonate at 10:00 p.m. on
the previous evening. The last pre-study dosage of enalapril was
taken in the morning at 6:30 a.m., and a light carbohydrate
breakfast was permitted at 7:00 a.m. Between 8:30 a.m. and 9:00
a.m. the subjects received an oral water load of 25 ml/kg.
Additional water was supplied throughout the clearance study,
matching urine output. The subjects remained supine except for
voiding. At 9:00 a.m. a continuous i.v. infusion of a solution
containing 10% inulin (polyfructosan) and 2.5% para-aminohip-
puric acid (PAH) was started, preceded by a priming dose.
After an equilibration period of 90 minutes, when urine osmo-
lality had reached a minimal value, the experimental protocol was
initiated. After two 20-minute baseline periods an infusion with
either Ang I or Mg II was started. Dosages were chosen such as
to obtain comparable levels of plasma Mg II. Ang I (5 g/ml
synthetic human Mg I, dissolved in 5% glucose; Cambridge
Research Biochemicals Ltd, Cambridge, UK) was administered as
a continuous intravenous infusion in increasing dosages of 4, 8, 16
and 32 pmol/kglmin. Ang II (1 g/ml synthetic human Mg II,
dissolved in 5% glucose; Cambridge Research Biochemicals Ltd,
Cambridge, UK) was infused in increasing dosages of 1 and 4
pmol/kg/min. Each infusion step was continued for 30 minutes,
and urine was collected at 15 minute intervals. Blood samples for
clearance determinations were obtained in the middle of each
collection period. Additional blood samples were taken for
plasma Mg I and II, plasma renin activity (PRA) and aldosterone
determination during the baseline collections and at the second
collection period of each angiotensin infusion rate. Throughout
the clearance study blood pressure was recorded with an auto-
matic sphygmomanometer device (Omega 1000, Invivo Research
Laboratories, Tulsa, OK, USA) at five minute intervals.
Analytical methods
Plasma Ang I and Ang II (pmollliter) were measured by radioim-
munoassay [17]. Blood was collected on ice with EDTA (final
concentration in plasma 15 mmol/liter), Ro 42-5892 (2 molJliter),
captopril (100 mo1/liter), o-phenantrolin (2 mmol/liter), neomycine
sulphate (0.3 mmol/liter) and PMSF (6 mol/liter) to inhibit the
activity of renin, ACE and angiotensinases. Collected in this way
and stored at —20°C, plasma angiotensins are stable for three
hours. The samples were stored as soon as possible at —80°C, at
which temperature they were stable for at least nine months. All
samples were processed within this period. All samples from each
subject were analyzed in one assay run. Mg I and Ang II were
extracted from 2 ml plasma (diluted with 8 ml 0.035 mmol/liter
HC1) by solid phase extraction chromatography using a vacuum
extraction device and butyl-silane extraction columns (Baker
Chemical Co, Deventer, the Netherlands), prewashed with meth-
anol and deionized water. The effluents were discarded, and the
columns were washed with 0.01 mmol/liter HC1 and eluted with
methanol/trifluoroacetic acid 99:1 vol/vol. The eluate was dried
and dissolved in assay buffer. Dilution curves of plasma extracts,
as well as standard curves containing aliquots of extract, were
parallel to the standard curves used in the radioimmunoassay.
Characteristics of the assays were: recoveiy of Mg I and Mg II
added to plasma prior to extraction, 73% and 90%, respectively
(reported data were corrected for these percentages); limit of
detection (three times SD at zero binding) 0.5 pmollliter; within-
assay and between-assays SD at plasma levels between 2 and 20
pmol/liter were 1.0 and 1.8 pmol/liter, respectively.
For the Mg II radioimmunoassay, a specific antibody with very
low cross reactivity against Mg I an Mg I peptide fragments was
used (Roche 923, courteously given by W. Fischli, F. Hoff-
mann-La Roche & Co, Basle, CH) [18]. Cross reactivities against
angiotensin peptides are: Mg I < 0.4%, Mg2_8 < 0.02%, Ang3_8
< 0.02%; Ang4_8 < 0.02%; Ang5_8 < 0.02%. Addition of a
mixture of Ang II peptide fragments and Ang I, resulting in the
presence of 50 fmol of each peptide per assay tube, to urine and
plasma samples with a low Mg II content (about 4 fmol/assay
tube) did not increase the apparent immunoreactive Mg II
concentration. Analysis of Mg II fractions obtained by HPLC of
these urine and plasma samples using the method previously
described by others [19] revealed similar concentrations as ob-
tained without HPLC. Cross reactivities of the Mg I antibody
against Mg II and Mg II peptide fragments were negligible
(<0.001%).
Plasma and urine sodium concentrations were measured by
flame photometry. Lithium was assessed using a Perkin-Elmer
3030 atomic absorption spectrophotometer. Osmolality was mea-
sured by means of an Advanced Digimatic Osmometer. Inulin was
measured photometrically with indolacetic acid after hydrolyza-
tion to fructose [20]. PAH was determined photometrically by a
chromogenic aldehyde reaction [21]. Plasma ACE activity was
measured using a colorimetric method by hydrolysis of the
synthetic substrate L-Hip-His-Leu [22]. PRA (fmol Mg I/liter!
second) and plasma aldosterone (pmol/liter) were measured by
radioimmunoassay [23].
Calculations, statistical analysis
Mean arterial pressure was calculated as the sum of one third of
the systolic pressure plus two thirds of the diastolic pressure. The
glomerular filtration rate (GFR) was assessed as inulin clearance,
the estimated renal plasma flow (ERPF) as PAH clearance. Both
were corrected for body surface area), and thus expressed in
ml/min/1.73 m2. Clearances and fractional excretions were calcu-
lated according to standard formula.
Data are presented as mean standard error of the mean
(sEM). Plasma Mg I, plasma Mg II, PRA, and aldosterone are
given as geometric means SEM, as these parameters were not
normally distributed. Statistical analysis was performed by one-
way analysis of variance for repeated measures (ANOVA). If the
variance ratio obtained by ANOVA reached statistical signifi-
cance, the differences between the means of observations were
analyzed by the method of the least significant difference (LSD),
using the ANOVA mean square error (pooled error variance) to
calculate the LSD at the 5% significance level. The comparison
between Mg I and Ang II responses was made by least squares
regression and analysis of covariance. Using this analysis, we also
calculated the least significant difference in response to Ang I
infusion compared to the response to Ang II infusion.
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Table 1. Plasma Ang I and II levels, renin activity, and aldosterone during intravenous infusion of Ang I and ACE inhibition
Angiotensin I infusion pmol/kg/min
Variable Baseline 4 8 16 32
Plasma angiotensin Ipmollliter 26 18 67 23 117 42 229 54' 578 120"
Plasma angiotensin II pmol/liter 3 1 4 1 8 3at, 15 3 29 5ab
Plasma renin activity fmol/liter/s 255 160 210 90 180 70 180 50 210 40
Plasma aldosterone pmol/liter 140 30 130 40 150 50 160 50 210 80
a p < 0.05 vs. baseline
b P < 0.05 vs. previous value
Table 2. Mean arterial pressure and renal clearance data during intravenous Ang I infusion and ACE inhibition
Angiotensin I infusion pmol/kg/min
Variable Baseline 4 8 16 32
Mean arterial pressure mm Hg 93 4 94 4 96 4 100 2 108 4'
C1 mI/mm 134 8 131 8 131 8 128 7 118 8
C1 mI/mm 621 31 590 18 543 37 500 18 459 25a
Filtration fraction % 22 2 22 1 24 2 26 2 26 2'
Urine flow mI/mm 20.6 1.4 18.6 1.3 16.7 isa 13.3 14ab 11.4
Sodium excretion pmol/min 324 43 287 38 230 36' 169 25ab 127 16at
Lithium clearance mI/mm 42.2 3.2 39.7 3.7 38.0 4.2a 34.5 3.8' 31.9 33a
Uric acid clearance mI/mm 10.0 0.5 9.3 0.8 8.9 0.8 7.8 08ab 6.8 07ab
a P < 0.05 vs. baseline
bP < 0.05 vs. previous value
Results
Adherence to the diet appears from the 24-hour urine sodium
excretion, which amounted to 324 28 and 333 19 mmol on the
two days prior to the clearance studies.
Infusion of the Ang I resulted in marked increases in plasma
Ang I concentration (Table 1). Although this infusion was carried
out against a background of enalapril treatment, plasma Ang II
increased as well. Plasma Ang II had increased significantly at an
Ang I infusion rate of 8 pmol/kg/min, and gradually increased
further with increasing plasma Ang I concentrations (Table 1).
The ACE activity determined in vitro was suppressed consistently
during the baseline period (0.04 0.02 mol/liter/second) and at
the end of the Ang I infusion (0.04 0.03 mol/liter/second; both
P < 0.01 compared to normal, range 0.3 to 1.2 .imo1/liter/second).
Plasma renin activity was not affected by the Ang I infusion.
Plasma aldosterone was significantly increased only during the 32
pmol/kg/min infusion rate.
At an Ang I infusion rate of 8 pmol/kg/min, mean arterial
pressure was significantly increased (Table 2), and increased
further during the higher Ang I infusion rates. Despite this
increase in arterial pressure, PAH clearance started to decrease at
an infusion rate of 8 pmol/kg/min. Inulin clearance showed a
significant decrease only at the highest infusion rate of 32
pmol/kg/min, and filtration fraction increased (Table 2). Ang I
infusion rates of 8 pmol/kg/min and higher also affected renal salt
handling. Maximal urine flow and sodium excretion decreased
significantly, as did lithium and uric acid clearance.
Ang II infusion, which was carried out against the same
background of enalapril treatment, was followed by an increase in
plasma Ang II concentration, in association with a decrease in
plasma Ang I (Table 3). Again, ACE activities were significantly
suppressed before (0.05 0.02 .tmolIliter/second) and during the
angiotensin infusion (0.05 0.02 jimol/liter/second) compared to
the normal range (P < 0.01). The plasma renin activity decreased,
Table 3. Plasma Ang I and II levels, renin activity, and aldosterone
during intravenous infusion of Ang II and ACE inhibition
Angiotensin II infusion
Variable Baseline
pmol/kg/min
1 4
Plasma angiotensin I 35 21 17 12 16 8
pmol/liter
Plasma angiotensin II 3 2 12 3 52 8'
pmol/Iiter
Plasma renin activity 280 160 210 110°' 170 85"
finol/liter/second
Plasma aldosterone 110 30 150 40 310 80°'
pmol/liter
a P < 0.05 vs. baseline
bP < 0.05 vs. previous value
and plasma aldosterone increased. Graded infusion of Ang II was
also accompanied by reductions in inulin and PAH clearances,
and with increments in filtration fraction and mean arterial
pressure (Table 4). At the same time maximal urine flow, sodium
excretion, and clearances of uric acid and lithium decreased.
A major purpose of this study was to compare the effects of Mg
I infusion to those of Ang II infusion at similar plasma concen-
trations of plasma Ang II. Individual data of the main variables
were therefore plotted against the individual values of plasma Ang
II obtained during Ang I infusion, and compared to the data
collected during Ang II infusion (Figs. 1 to 5). In some occasions
the levels of plasma Ang II obtained during the highest dosage of
Ang II exceeded the levels obtained during Ang I infusion. Since
we aimed to compare the effects of Ang I infusion and Mg II
infusion within a similar range of changes in plasma Mg II, the
data corresponding to these excessive plasma Ang II levels were
not included in the evaluation. The statistical evaluation of these
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Table 4. Mean arterial pressure and renal clearance data during
intravenous Ang II infusion and ACE inhibition
Angiotensin II infusion
Variable Baseline
pmol/kglmin
1 4
Mean arterial pressure mm Hg
C ml/min
CPAH mI/mm
92 3
138 9
695 64
98 3 110 2
128 6 6ab
521 28 370 25'
Filtration fraction % 20 1 25 ia 30 2at
Urine flow mI/mm 20.7 1.8 13.3 1.4 7.4 12ab
Sodium excretion u'nolImin
Lithium clearance ml/min
331 40
43.5 4.2
135 23 65 17'
30.4 2.5a 18.8 30ab
Uric acid clearance mI/mm 10.8 0.7 7.9 Q7a 5.1 0.7
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Fig. 1. Regression lines and 95% confidence limits for mean arterial pres-
sure, expressed as percentage of the control values (MAP%), and plasma Ang
II levels during Ang I (solid lines, •) and Ang II infusion (dashed lines, 0)
following 5 days of ACE inhibitor administration. A positive correlation
could be demonstrated for both infusion protocols (Table 5).
plots, including comparison between the correlations obtained
during Ang I and Ang II infusion, is presented in Table 5.
Positive correlations were found for changes in plasma Ang II
and mean arterial pressure, with no perceptable difference be-
tween the observations during Ang I and Ang II infusion (Fig. 1).
Similarly, plasma aldosterone levels were positively correlated to
plasma Ang II levels (Fig. 2), with no distinction between the
correlations found during infusion of Ang I or Ang II (Table 5).
However, during neither infusion a significant correlation be-
tween changes in plasma Ang II and PRA was found. Strong
negative correlations were found between changes in plasma Ang
II and ERPF in both the Ang I and Ang II infusion study (Fig. 3).
Again, the relation between plasma Ang II levels and ERPF was
not perceptably different between the Ang I and Ang II infusion
studies. Increasing plasma Ang II levels were not significantly
correlated to GFR during Ang I infusion (Fig. 1); however, a weak
correlation could be demonstrated during Ang II infusion (Table
5). Urine sodium excretion, maximal urine flow (Fig. 4), and
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Fig. 2. Regression lines and 95% confidence limits for plasma aldosterone
(A) and plasma renin activity (B) dunng Ang I (solid lines, •) and Ang II
infusion (dashed lines, 0) following 5 days of ACE inhibitor administration.
Weak positive correlations were found in both protocols (Table 5). No
significant correlations were found between plasma renin activity and
plasma Ang 11(B).
lithium clearance (Fig. 5) showed strong negative correlations
with the prevailing Ang II levels in both studies and these
relations were also congruent for Ang I and Ang II infusion.
Table 5 also shows the regression coefficients of hypothetical
curves (plasma Ang II vs. effect) that would indicate the least
significantly (P  0.05) greater effect than observed during Ang II
infusion. This evaluation indicates that an about 30 to 50%
greater effect on arterial pressure and intrarenal changes by Ang
I infusion compared to Ang II infusion would have been recog-
nized by the present experimental methods as significantly
greater. For aldosterone, about an 80% larger effect would have
been recognized as significantly greater.
Discussion
The present study evaluated the efficacy of the ACE inhibitor
enalapril to block systemic and renal Ang II formation, by
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Fig. 3. Regression lines and 95% confidence limits for PAH clearance
(CPAH, A) and inulin clearance (C,,,, B) and plasma Ang II levels during
Ang I (solid lines, •) andAng II infusion (dashed lines, 0) following 5 days
of ACE inhibitor administration. CPAH correlated with plasma Ang II levels
during both Ang I and Ang II infusion (Table 5). No correlation could be
demonstrated between Ang II levels and C1,, during the Ang I infusion
protocol, although a weak correlation could be demonstrated between C1,,
and plasma Ang II levels in the Ang II infusion study.
comparing the functional responses to Ang I and Ang II infusion.
Ang II infusion resulted in elevated plasma Ang II levels, which
strongly correlated with increments in systemic blood pressure
and with decrements in renal plasma flow and sodium, lithium and
volume excretion. Ang I infusion during ACE inhibitor treatment
also resulted in increments in plasma Ang II levels. The plasma
Ang II concentration-response profiles were similar as during Ang
II infusion for both systemic blood pressure and renal plasma flow
and renal salt handling.
Efficacy of ACE inhibition is highly related to the extent of
suppression of conversion of Ang I to Ang II. Enalapril, in the
presently applied dosage, markedly suppressed plasma ACE
Plasma Ang II, pmol/liter
Fig. 4. Regression lines and 95% confidence limits for urine sodium excre-
tion (UN,,V A) and urine flow (B) and plasma Ang II levels during Ang I
(solid lines, •) andAng II infusion (dashed lines, 0) followingS days ofACE
inhibitor administration. Sodium excretion and urine flow correlated well
with plasma Ang II levels during both protocols (Table 5).
activity, as assessed in vitro using a synthetic substrate. The lowest
rate of Ang I infusion increased plasma Ang I several-fold, but
had no effect on plasma Ang II, suggesting that residual conver-
sion of endogenous Ang I was probably minimal. Nonetheless,
Ang II formation was not completely blocked, as was shown by the
significant increase in plasma Ang II concentration during Ang I
infusion rates exceeding 4 pmol/kglmin. This discrepancy between
ACE activity assessed in vitro with a synthetic substrate and in vivo
as the Ang hAng II ratio is similar as reported by others [24] and
can be attributed to remaining ACE activity [6—8, 24] as well as to
conversion through alternative pathways [9—10]. Both ACE activ-
ity as determined in vitro with artificial substrates [24], and the
plasma Ang hl/Ang I ratio as an indicator of ACE activity leave
uncertainty with respect to suppression of Ang II formation
remaining in the kidney. Local peptidases, not affected by ACE
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inhibitors, such as cathepsin G, tonin and tissue-plasminogen
activator [9] or local upregulation of ACE expression [8] could
create higher Mg II concentrations at tissue level than can be
appreciated from plasma Ang II levels. Furthermore, several
studies have demonstrated that whole kidney [25] and proximal
tubular fluid [26, 27] Mg II levels can dissociate widely from
plasma levels. In addition, up-regulation of Mg II receptors
during ACE inhibitor administration has been demonstrated [28].
These and other studies emphasize that limited information can
be derived from plasma ACE, Mg I and Ang II levels on activity
of the intrarenal renin-angiotensin system.
Since there are currently no direct methods available to assess
renal Mg II formation in humans, we examined whether infor-
mation on intrarenal Mg II formation can be obtained indirectly
by comparing the plasma Mg II concentration-response profiles
during Ang I and Mg II infusion. To compare these profiles, close
correlations between plasma Mg II levels and systemic and renal
responses should exist and the Mg II levels measured during Ang
I and Mg II infusion should be in a similar range. Both conditions
were met: the changes in arterial pressure, plasma aldosterone,
ERPF and sodium and water excretion during Mg II infusion
highly correlated with the plasma Ang II levels, and the infusion
rates of Mg I and of Mg II resulted in plasma Mg II levels in a
similar range. Importantly too, correlations between increments
in blood pressure and plasma Ang II were entirely congruent
during Mg I and Ang II infusion. This excludes that correlations
between plasma Mg II and renal responses were modulated
differently by direct renal effects of blood pressure elevation.
If intrarenal Ang II formation were less affected by ACE
inhibitor administration than systemic Mg II formation, a steeper
relationship between prevailing plasma Mg II levels and renal
sodium and water excretion was to be expected than during Mg
II infusion. However, this was not the case: the decrease in sodium
and water excretion correlated with the measured plasma Mg II
levels in a remarkably similar fashion during Ang I infusion and
during Mg II infusion. For the decrease in lithium clearance,
which can be taken as an indicator of stimulated proximal tubule
reabsorption by Ang II [29], the relationship tended to be less
steep rather than steeper during Ang I infusion. The latter was
also the ease for ERPF. Apparently, the widely differing plasma
Mg I concentrations in these situations, being elevated substan-
tially during Mg I infusion, and suppressed during Mg II
infusion, had no effect in the kidney which was independent of the
change in plasma Mg II. A similar conclusion can be drawn for
the increments in blood pressure and plasma aldosterone. On the
other hand, a formal comparison between the results of Ang I and
Ang II infusion is not possible with regard to changes in PRA.
Suppression of PRA by the angiotensin infusions was at most
modest, and no correlation was found between changes in plasma
Mg II and PRA. Relative maintenance of GFR during Mg II
infusion makes this variable also less suitable for the present
100 purpose, because the decrement in GFR was small in relation to
the decrement in ERPF, resulting in the well-documented in-
crease in filtration fraction [11, 30]. Thus, the results of the
present experimental setting do not support that intrarenal and
systemic Mg Ito Mg II conversion during enalapril administra-
tion are dissociated to such an extent that this is functionally
diseernable. It should be emphasized that our findings do not
dispute that a difference between systemic and renal ACE inhibi-
tion can exist when other ACE inhibitors than enalapril or
different dosages are applied. Persistent renal vasoconstrictive
action of Mg I despite adequate systemic ACE inhibition has
indeed been demonstrated in several animal experiments [14—16].
The present data should be interpreted with appropriate cau-
tion, since, by necessity in this study in humans, indirect methods
were applied. To assess the sensitivity of the experimental setting
to detect differences in response to Ang I and Mg II infusion, we
also estimated how much greater effect during Ang I infusion
compared to Mg II infusion would have been recognized as
significant. This evaluation indicated that, for the intrarenal
effects, an about 40% larger effect of Mg I infusion compared to
Mg II infusion would be required, implying an about 40% greater
intrarenal formation of Ang II than indicated by the plasma levels
of Ang II. The most prudent conclusion from the present renal
function data would therefore be that, if intrarenal Ang II
formation in the kidney would indeed exceed that in plasma, the
difference cannot exceed 40%. However, the similarity in regres-
sion coefficients and the overlap in responses found during Mg I
and Ang II infusion suggest that, in fact, a difference was non
existent, or anyhow much smaller.
In humans, the present observations could be of particular
relevance in hypertension and cardiac failure. Reports of near-
normal plasma Mg II levels observed during ACE inhibition [31,
32] have raised the question, how ACE inhibitors are capable of
reducing blood pressure in hypertensive subjects. It has been
suggested that the reported plasma Mg II levels are artifacts
induced by cross reactivity of the Mg II antiserum with Ang I in
the radioimmunoassays [31, 32]. However, our finding of physio-
logical actions that are compatible with the prevailing Ang II
concentrations measured by the assay, makes this option unlikely.
Furthermore, other investigators who used high performance
liquid chromatography to separate angiotensin peptides prior to
the radioimmunoassay, have demonstrated low, but not undetect-
able plasma Mg II levels [32]. The data from the present
investigation are in accordance with the data obtained by
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Fig. S. Regression lines and 95% confidence limits for lithium clearance and
plasma Ang II levels duringAng I (solid lines, .) and Ang II infusion (dashed
lines, 0) following 5 days of ACE inhibitor administration. A negative
correlation could be demonstrated for both infusion protocols (Table 5).
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Table 5. Correlation between plasma Ang II levels and measured parameters for the Ang I and the Aug II infusion study
Ang I infusion Ang II infusion
P10 Slope005Slope Intercept r P Slope Intercept r P
MAP (% change)
Plasma aldosterone
CPAH
C1,,
UNaV
Urine flow
CL,
13
62
—120
—10
—227
—9.1
—14.3
95
56
586
122
427
24.4
49.7
0.76
0.44
—0.55
—0.21
—0.84
—0.83
—0.61
<0.001
0.004
<0.001
0.18
<0.001
<0.001
<0.001
15
83
—212
—16
—234
—10.5
—19.9
94
56
692
128
426
25.1
52.5
0.89
0.50
—0.64
—0.43
—0.80
—0.80
—0.76
<0.001
0.013
<0.001
0.035
<0.001
<0.001
<0.001
0.42
0.54
0.11
—
0.86
0.45
0.23
21
153
—325
—
—318
—14.0
—29.2
Analysis of covariance revealed no significant differences between the slopes and intercepts obtained in both studies.
Abbreviations are: MAP, mean arterial pressure; CPAH, PAH clearance; C1, inulin clearance; UNaV, sodium excretion; CLI, lithium clearance; P,01,,,,
significance of regression coefficients during Ang I and Ang II infusion; slope005, value that regression coefficients during Ang I infusion should have
in order to differ significantly from those obtained during Ang II infusion.
Hannedouche et a! [33] and indicate that despite the presence of
an ACE inhibitor, the well known actions of Ang II to increase
peripheral resistance and to enhance renal sodium reabsorption
are still present. In cardiac failure potential importance of disso-
ciative actions of ACE inhibitors consists of systemic vasorelax-
ation while avoiding too large decrease in glomerular pressure
and filtration [34] or, alternatively, to facilitate renal sodium
excretion in the absence of a large fall in blood pressure and
glomerular filtration [35]. The present protocol provides a tool to
evaluate whether such dissociation can be achieved.
Summarizing, the current study evaluated whether Ang I
infusion during ACE inhibition can be used as a functional test to
assess intrarenal versus systemic blockade of Ang II formation.
Both Ang I and Ang II infusion resulted in elevated plasma Ang
II levels in a similar range. Close correlations between plasma
Ang II concentration and mean arterial pressure, ERPF and renal
sodium handling could be demonstrated in both protocols. This
study suggests that the present protocol can be employed to test
the efficacy of intrarenal versus systemic ACE inhibition in
humans. During the presently applied dosage of enalapril, the
similarity of the plasma Ang II concentration-response profiles
during infusion of Ang I and II suggests that systemic and renal
Ang II formation were inibited to the same extent. A similar
strategy can be used to assess the efficacy of intrarenal ACE
inhibition during alternative ACE inhibitor regimens or in disease
states.
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